(PAND) – FDA
-
Pandion Therapeutics (PAND) Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting
-
Pandion Therapeutics (PAND) Reports Positive Top-Line Phase 1a Clinical Data Demonstrating Proof of Mechanism of PT101
Back to PAND Stock Lookup